Vertex Pharmaceuticals Incorporated (vrtx)
VRTX — Company Overview
Vertex Pharmaceuticals Incorporated (VRTX) trades on NMS as part of the Healthcare peer group (Biotechnology).
| Ticker | VRTX |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $130.87B |
| Last price | $516.34 |
| Size category | Large Cap |
VRTX — Business Description
VRTX represents a Biotechnology business in the Healthcare segment. Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older…
Official website: https://www.vrtx.com.
VRTX — Investment Thesis
At a high level, VRTX offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is expanding at roughly 12.5% year-over-year (public data).
- Trailing P/E of 30.04× sits in a moderate band relative to high-growth peers.
- Forward P/E (25.70×) is below trailing P/E — earnings may be expected to improve.
- Equity market capitalization is approximately $130.87B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
VRTX — Financial Health
Key financial health indicators for Vertex Pharmaceuticals Incorporated are derived exclusively from public data — no proprietary estimates.
Profit margin of 35.0% indicates solid bottom-line conversion. Positive free cash flow of $2.63B supports balance-sheet flexibility.
| Trailing P/E | 30.04× |
| Forward P/E | 25.70× |
| Price / Sales | 10.39× |
| Price / Book | 6.46× |
| Gross margin | 55.0% |
| Operating margin | 38.1% |
| Profit margin | 35.0% |
| Return on equity | 23.5% |
| Debt / Equity | 9.77 |
| Free cash flow | $2.63B |
VRTX — Growth Outlook
Growth outlook for Vertex Pharmaceuticals Incorporated (VRTX) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 12.5% indicates strong top-line momentum.
- Earnings growth of 8.0% year-over-year supports improving profitability.
- Price is 7.8% below the 52-week high.
VRTX — Competitive Position
Vertex Pharmaceuticals Incorporated (VRTX) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $130.87B places VRTX among large-cap peers.
- Gross margin near 55.0% may reflect pricing power or favorable mix.
VRTX — Strengths
Strengths for Vertex Pharmaceuticals Incorporated (VRTX) inferred from public financial metrics:
- Revenue growth of 12.5% year-over-year.
- Earnings growth of 8.0% year-over-year.
- Return on equity near 23.5% — efficient use of shareholder capital.
- Gross margin of 55.0% supports competitive unit economics.
- Positive free cash flow ($2.63B).
- Moderate leverage (debt/equity 9.77).
VRTX — Weaknesses
Weaknesses and pressure points for Vertex Pharmaceuticals Incorporated (VRTX) based on available data:
Insufficient public data to assess this factor.
VRTX — Opportunities
- Sustained revenue growth (12.5%) could support multiple expansion if margins hold.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
VRTX — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
VRTX — Summary
Vertex Pharmaceuticals Incorporated (VRTX) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $516.34 with market cap $130.87B. Trailing P/E 30.04×. Revenue grew 12.5% year-over-year per public data. Notable strengths include revenue growth of 12.5% year-over-year. Premium Terminal tools for Vertex Pharmaceuticals Incorporated add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open VRTX in Vest Terminal
Access live data, filings, ownership, and analysis for Vertex Pharmaceuticals Incorporated.
Vertex Pharmaceuticals Incorporated FAQ
What does Vertex Pharmaceuticals Incorporated (VRTX) do?
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell di…
What is VRTX's P/E ratio?
Vertex Pharmaceuticals Incorporated has a trailing P/E of 30.04× based on publicly available market data.
Does VRTX pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is VRTX in?
Vertex Pharmaceuticals Incorporated is classified in Healthcare (Biotechnology) on NMS.
What is VRTX's market capitalization?
Approximate market cap: $130.87B.
What are the main risks for VRTX?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of VRTX?
Potential positives include revenue growth of 12.5% year-over-year, earnings growth of 8.0% year-over-year.
Where can I get analyst estimates for VRTX?
Public analyst price targets and consensus for Vertex Pharmaceuticals Incorporated are on the free /stocks/vrtx/estimates page. Deeper estimate history and models are available in Vest Terminal.